Cargando…
A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri
Frog skin secretions contain complex peptidomes and peptidic protease inhibitors that are one of the biologically and structurally described groups of components. In the present study, by use of molecular ‘shotgun’ cloning and LC MS/MS fractionation sequencing, a novel Bowman–Birk-type heptadecapept...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408667/ https://www.ncbi.nlm.nih.gov/pubmed/28356487 http://dx.doi.org/10.1042/BSR20160593 |
_version_ | 1783232343013588992 |
---|---|
author | Wu, Yuxin Long, Qilin Xu, Ying Guo, Shaodong Chen, Tianbao Wang, Lei Zhou, Mei Zhang, Yingqi Shaw, Chris Walker, Brian |
author_facet | Wu, Yuxin Long, Qilin Xu, Ying Guo, Shaodong Chen, Tianbao Wang, Lei Zhou, Mei Zhang, Yingqi Shaw, Chris Walker, Brian |
author_sort | Wu, Yuxin |
collection | PubMed |
description | Frog skin secretions contain complex peptidomes and peptidic protease inhibitors that are one of the biologically and structurally described groups of components. In the present study, by use of molecular ‘shotgun’ cloning and LC MS/MS fractionation sequencing, a novel Bowman–Birk-type heptadecapeptide (AALKGCWTKSIPPKPCF-amide), named Odorrana schmackeri Trypsin Inhibitor (OSTI), with a canonical Cys(6)–Cys(16) disulfide bridge, was isolated and identified in piebald odorous frog (O. schmackeri) skin secretion. A synthetic replicate of OSTI-exhibited trypsin inhibitory activity with a K(i) value of 0.3 ± 0.04 nM and also a tryptase inhibitory effect with a K(i) of 2.5 ± 0.6 μM. This is the first time that this property has been reported for a peptide originating from amphibian sources. In addition, substituting lysine (K) with phenylalanine (F) at the presumed P1 position, completely abrogated the trypsin and tryptase inhibition, but produced a strong chymotrypsin inhibition with a K(i) of 1.0 ± 0.1 μM. Thus, the specificity of this peptidic protease inhibitor could be optimized through modifying the amino acid residue at the presumed P1 position and this novel native OSTI, along with its analogue, [Phe(9)]-OSTI, have expanded the potential drug discovery and development pipeline directed towards alleviation of serine protease-mediated pathologies. |
format | Online Article Text |
id | pubmed-5408667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54086672017-05-04 A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri Wu, Yuxin Long, Qilin Xu, Ying Guo, Shaodong Chen, Tianbao Wang, Lei Zhou, Mei Zhang, Yingqi Shaw, Chris Walker, Brian Biosci Rep Research Articles Frog skin secretions contain complex peptidomes and peptidic protease inhibitors that are one of the biologically and structurally described groups of components. In the present study, by use of molecular ‘shotgun’ cloning and LC MS/MS fractionation sequencing, a novel Bowman–Birk-type heptadecapeptide (AALKGCWTKSIPPKPCF-amide), named Odorrana schmackeri Trypsin Inhibitor (OSTI), with a canonical Cys(6)–Cys(16) disulfide bridge, was isolated and identified in piebald odorous frog (O. schmackeri) skin secretion. A synthetic replicate of OSTI-exhibited trypsin inhibitory activity with a K(i) value of 0.3 ± 0.04 nM and also a tryptase inhibitory effect with a K(i) of 2.5 ± 0.6 μM. This is the first time that this property has been reported for a peptide originating from amphibian sources. In addition, substituting lysine (K) with phenylalanine (F) at the presumed P1 position, completely abrogated the trypsin and tryptase inhibition, but produced a strong chymotrypsin inhibition with a K(i) of 1.0 ± 0.1 μM. Thus, the specificity of this peptidic protease inhibitor could be optimized through modifying the amino acid residue at the presumed P1 position and this novel native OSTI, along with its analogue, [Phe(9)]-OSTI, have expanded the potential drug discovery and development pipeline directed towards alleviation of serine protease-mediated pathologies. Portland Press Ltd. 2017-04-28 /pmc/articles/PMC5408667/ /pubmed/28356487 http://dx.doi.org/10.1042/BSR20160593 Text en © 2017 The Author(s). http://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Articles Wu, Yuxin Long, Qilin Xu, Ying Guo, Shaodong Chen, Tianbao Wang, Lei Zhou, Mei Zhang, Yingqi Shaw, Chris Walker, Brian A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri |
title | A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri |
title_full | A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri |
title_fullStr | A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri |
title_full_unstemmed | A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri |
title_short | A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri |
title_sort | structural and functional analogue of a bowman–birk-type protease inhibitor from odorrana schmackeri |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408667/ https://www.ncbi.nlm.nih.gov/pubmed/28356487 http://dx.doi.org/10.1042/BSR20160593 |
work_keys_str_mv | AT wuyuxin astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT longqilin astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT xuying astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT guoshaodong astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT chentianbao astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT wanglei astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT zhoumei astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT zhangyingqi astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT shawchris astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT walkerbrian astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT wuyuxin structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT longqilin structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT xuying structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT guoshaodong structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT chentianbao structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT wanglei structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT zhoumei structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT zhangyingqi structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT shawchris structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri AT walkerbrian structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri |